Pharmacokinetics of metronomic chemotherapy: A neglected but crucial aspect

Nature Reviews Clinical Oncology

Volumn 13, Issue 11, 2016, Pages 659-673

  Bocci, Guido ^a   Kerbel, Robert S ^b,c  

^a UNIVERSITY OF PISA   (Italy)

^b Institute of Clinical Evaluative Sciences   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; FLUOROPYRIMIDINE DERIVATIVE; MICROTUBULE BINDING AGENT; UNCLASSIFIED DRUG; 5-FLUOROPYRIMIDINE; CAMPTOTHECIN; PYRIMIDINE DERIVATIVE; TUBULIN MODULATOR;

AREA UNDER THE CURVE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; HUMAN; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; METASTATIC COLORECTAL CANCER; METRONOMIC DRUG ADMINISTRATION; MINIMUM PLASMA CONCENTRATION; NONHUMAN; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PHARMACOKINETICS; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR IMMUNITY; VOLUME OF DISTRIBUTION AT STEADY-STATE; BREAST NEOPLASMS; CELLULAR IMMUNITY; COLORECTAL NEOPLASMS; FEMALE; FORECASTING; IMMUNOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC);

ADMINISTRATION, METRONOMIC; ALKYLATING AGENTS; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CAMPTOTHECIN; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; FEMALE; FORECASTING; HUMANS; IMMUNITY, CELLULAR; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUBULIN MODULATORS;

EID: 84994176321     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2016.64     Document Type: Review

References (153)

1. Kerbel, R. S., & Kamen, B. A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4, 423-436 (2004
2. Andre, N., Carre, M., & Pasquier, E. Metronomics: towards personalized chemotherapy? Nat. Rev. Clin. Oncol. 11, 413-431 (2014
3. Munzone, E., & Colleoni, M. Clinical overview of metronomic chemotherapy in breast cancer. Nat. Rev. Clin. Oncol. 12, 631-644 (2015
4. Browder, T., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60, 1878-1886 (2000
5. Klement, G., et al. Continuous low-dose therapy with vinblastine and VEGF receptor 2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, R15-R24 (2000).
6. Bocci, G., Nicolaou, K. C., & Kerbel, R. S. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 62, 6938-6943 (2002
7. Hao, Y. B., Yi, S. Y., Ruan, J., Zhao, L., & Nan, K. J. New insights into metronomic chemotherapy-induced immunoregulation. Cancer Lett. 354, 220-226 (2014
8. Folkins, C., et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res. 67, 3560-3564 (2007
9. Derosa, L., et al. Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients. Cancer 120, 3923-3931 (2014
10. Shaked, Y., et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res. 65, 7045-7051 (2005
11. Jedeszko, C., et al. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. Sci. Transl. Med. 7, 282ra50 (2015
12. Cruz-Munoz, W., et al. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer. Angiogenesis 17, 661-673 (2014
13. Srivastava, K., et al. Postsurgical adjuvant tumor therapy by combining anti-angiopoietin 2 and metronomic chemotherapy limits metastatic growth. Cancer Cell 26, 880-895 (2014
14. Dellapasqua, S., et al. Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab. Breast 21, 309-313 (2012
15. Bocci, G., et al. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor 2 monoclonal antibodies. Cancer Res. 64, 6616-6625 (2004
16. Orlando, L., et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER 2 positive metastatic breast cancer. BMC Cancer 6, 225 (2006
17. Denies, S., Cicchelero, L., Van Audenhove, I., & Sanders, N. N. Combination of interleukin 12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication. J. Control. Release 187, 175-182 (2014
18. Weir, G. M., et al. Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T cell mediated antitumor immune response. Oncoimmunology 3, e953407 2014
19. Bottini, A., et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J. Clin. Oncol. 24, 3623-3628 (2006
20. Emmenegger, U., et al. Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice. Mol. Cancer Ther. 6, 2280-2289 (2007
21. Wang, Z., Butner, J. D., Cristini, V., & Deisboeck, T. S. Integrated PK PD and agent-based modeling in oncology. J. Pharmacokinet. Pharmacodyn. 42, 179-189 (2015
22. Penel, N., et al. Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care. Br. J. Cancer 102, 1207-1212 (2010
23. Patil, V. M., et al. A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. Oral Oncol. 51, 279-286 (2015
24. Chen, Y. M., et al. A phase II randomized trial of gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. J. Thorac. Oncol. 6, 1110-1116 (2011
25. Simkens, L. H., et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 385, 1843-1852 (2015
26. Rowland, M., & Tozer, T Nin Clinical Pharmacokinetics: Concepts and Applications 53-105 (Lippincot Williams, & Wilkins 1995
27. Gillis, N. K., Patel, J. N., & Innocenti, F. Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era. Clin. Pharmacol. Ther. 95, 269-280 2014
28. Roy, P., & Waxman, D. J. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer. Toxicol. In Vitro 20, 176-186 (2006
29. Bocci, G., et al. A pharmacokinetic-based test to prevent severe 5 fluorouracil toxicity. Clin. Pharmacol. Ther. 80, 384-395 (2006
30. Kerbel, R. S., & Grothey, A. Gastrointestinal cancer: rationale for metronomic chemotherapy in phase III trials. Nat. Rev. Clin. Oncol. 12, 313-314 (2015
31. Fan, J., & De Lannoy, I. A. Pharmacokinetics. Biochem. Pharmacol. 87, 93-120 (2014
32. Barbolosi, D., et al. Metronomics chemotherapy: time for computational decision support. Cancer Chemother. Pharmacol. 74, 647-652 (2014
33. McCune, J. S., Jacobson, P., Wiseman, A., & Militano, O. Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics. Bone Marrow Transplant. 50, 165-172 (2015
34. Widmer, N., et al. Review of therapeutic drug monitoring of anticancer drugs part two- targeted therapies. Eur. J. Cancer 50, 2020-2036 (2014
35. Zhou, Q., Guo, P., Wang, X., Nuthalapati, S., & Gallo, J. M. Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. J. Pharmacol. Exp. Ther. 321, 265-275 (2007
36. Banissi, C., Ghiringhelli, F., Chen, L., & Carpentier, A. F. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol. Immunother. 58, 1627-1634 (2009
37. Penel, N., Adenis, A., & Bocci, G. Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going? Crit. Rev. Oncol. Hematol. 82, 40-50 (2012
38. Bocci, G., Francia, G., Man, S., Lawler, J., & Kerbel, R. S. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc. Natl Acad. Sci. USA 100, 12917-12922 (2003
39. Man, S., et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 62, 2731-2735 (2002
40. Klink, T., et al. Metronomic trofosfamide inhibits progression of human lung cancer xenografts by exerting anti-angiogenic effects. J. Cancer Res. Clin. Oncol. 132, 643-652 (2006
41. Chen, C. S., Doloff, J. C., & Waxman, D. J. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression. Neoplasia 16, 84-96 (2014
42. Bocci, G., Di Paolo, A., & Danesi, R. The pharmacological bases of the antiangiogenic activity of paclitaxel. Angiogenesis 16, 481-492 (2013
43. Di Paolo, A., Bocci, G., & Danesi, R. The preclinical bases of the rational combination of paclitaxel and antiangiogenic drugs. Clin. Cancer Drugs 1, 100-115 (2014
44. Pasquier, E., Andre, N., & Braguer, D. Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment. Curr. Cancer Drug Targets 7, 566-581 (2007
45. Schwartz, E. L. Antivascular actions of microtubule-binding drugs. Clin. Cancer Res. 15, 2594-2601 (2009
46. Huang, Y., et al. Antiangiogenic activity of sterically stabilized liposomes containing paclitaxel (SSL-PTX): in vitro and in vivo. AAPS PharmSciTech 11, 752-759 (2010
47. Koziara, J. M., Whisman, T. R., Tseng, M. T., & Mumper, R. J. In vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J. Control. Release 112, 312-319 (2006
48. Hammady, T., Rabanel, J. M., Dhanikula, R. S., Leclair, G., & Hildgen, P. Functionalized nanospheres loaded with anti-angiogenic drugs: cellular uptake and angiosuppressive efficacy. Eur. J. Pharm. Biopharm. 72, 418-427 (2009
49. Ng, S. S., et al. Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL based paclitaxel. Clin. Cancer Res. 12, 4331-4338 (2006
50. Miele, E., Spinelli, G. P., Tomao, F., & Tomao, S. Albumin-bound formulation of paclitaxel (Abraxane- ABI 007) in the treatment of breast cancer. Int. J. Nanomedicine 4, 99-105 (2009
51. Lee, S. J., et al. Metronomic activity of CD44 targeted hyaluronic acid-paclitaxel in ovarian carcinoma. Clin. Cancer Res. 18, 4114-4121 (2012
52. Luo, L. M., et al. Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel. Biomaterials 34, 1102-1114 (2013
53. Bradshaw-Pierce, E. L., Eckhardt, S. G., & Gustafson, D. L. A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin. Cancer Res. 13, 2768-2776 (2007
54. Bradshaw-Pierce, E. L., Steinhauer, C. A., Raben, D., & Gustafson, D. L. Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma. Mol. Cancer Ther. 7, 3006-3017 (2008
55. Kumar, S., et al. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin. Cancer Res. 17, 5656-5667 (2011
56. Van Geel, R M., Beijnen, J. H., & Schellens, J. H. Concise drug review: pazopanib and axitinib. Oncologist 17, 1081-1089 (2012
57. Hartmann, J. T., & Lipp, H. P. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II- mechanisms of action, pharmacokinetics and toxicity profile. Drug Saf. 29, 209-230 (2006
58. Andre, N., Padovani, L., & Verschuur, A. Metronomic chemotherapy: back to the future! Drug News Perspect 23, 143-151 2010
59. Allegrini, G., et al. A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. Br. J. Cancer 98, 1312-1319 (2008
60. Tillmanns, T. D., et al. Daily oral topotecan: utilization of a metronomic dosing schedule to treat recurrent or persistent solid tumors. J. Clin. Oncol. 26, 2571 (2008
61. Turner, D. C., Tillmanns, T. D., Harstead, K. E., Throm, S. L., & Stewart, C. F. Combination metronomic oral topotecan and pazopanib: a pharmacokinetic study in patients with gynecological cancer. Anticancer Res. 33, 3823-3829 (2013
62. Briasoulis, E., et al. Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin. Cancer Res. 15, 6454-6461 (2009
63. Briasoulis, E., et al. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer 13, 263 (2013
64. Allegrini, G., et al. Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis 15, 275-286 (2012
65. Moes, J., et al. Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel. Eur. J. Pharm. Biopharm. 83, 87-94 (2013
66. Bazzola, L., et al. Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. Br. J. Cancer 112, 52-60 (2015
67. Stempak, D., et al. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J. Pediatr. Hematol. Oncol. 28, 720-728 (2006
68. Baruchel, S., et al. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur. J. Cancer 42, 2335-2342 (2006
69. Haefeli, W. E., & Carls, A. Drug interactions with phytotherapeutics in oncology. Expert Opin. Drug Metab. Toxicol. 10, 359-377 (2014
70. Roby, C. A., Anderson, G. D., Kantor, E., Dryer, D. A., & Burstein, A. H. St John-s Wort: effect on CYP3A4 activity. Clin. Pharmacol. Ther. 67, 451-457 (2000
71. Leveque, D., et al. Mechanisms of pharmacokinetic interactions involving oral anticancer agents. Bull. Cancer 102, 65-72 (2015
72. Lasalvia-Prisco, E., et al. Insulin-induced enhancement of antitumoral response to methotrexate in breast cancer patients. Cancer Chemother. Pharmacol. 53, 220-224 (2004
73. Damyanov, C., Gerasimova, D., Maslev, I., & Gavrilov, V. Low-dose chemotherapy with insulin (insulin potentiation therapy) in combination with hormone therapy for treatment of castration-resistant prostate cancer. ISRN Urol. 2012, 140182 (2012
74. Chen, C., Xu, T., Lu, Y., Chen, J., & Wu, S. The efficacy of temozolomide for recurrent glioblastoma multiforme. Eur. J. Neurol. 20, 223-230 (2013
75. Adenis, A., et al. A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours. Br. J. Cancer 109, 2574-2578 (2013
76. Villano, J. L., Seery, T. E., & Bressler, L. R. Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother. Pharmacol. 64, 647-655 (2009
77. US National Library of Science ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT01285817-term=NCT01285817& rank=1 (2015
78. US National Library of Science. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT00200161-term=NCT00200161& rank=1 (2015
79. Di Paolo, A., Bocci, G., Danesi, R., & Del Tacca, M. Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients. Curr. Clin. Pharmacol. 1, 311-323 (2006
80. Falcone, A. et al. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. J. Clin. Oncol. 19, 3456-3462 (2001).
81. Herben, V. M., et al. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors. J. Clin. Oncol. 17, 1897-1905 (1999
82. Bocci, G., et al. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br. J. Cancer 98, 1619-1629 (2008
83. Hashimoto, K., et al. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol. Cancer Ther. 9, 996-1006 (2010
84. Merritt, W. M., et al. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol. Ther. 8, 1596-1603 (2009
85. Minturn, J. E., et al. A phase II study of metronomic oral topotecan for recurrent childhood brain tumors. Pediatr. Blood Cancer 56, 39-44 (2011
86. Herben, V. M., et al. Oral topotecan: bioavailablity and effect of food co administration. Br. J. Cancer 80, 1380-1386 (1999
87. Schellens, J. H., et al. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br. J. Cancer 73, 1268-1271 (1996
88. Kerklaan, B. M., et al. Phase I study of safety, tolerability, and pharmacokinetics of pazopanib in combination with oral topotecan in patients with advanced solid tumors. J. Clin. Oncol. 31, 2536 (2013
89. Kerklaan, B. M., et al. Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours. Br. J. Cancer 113, 706-715 (2015
90. Cazzaniga, M. E., et al. Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development. Future Oncol. 12, 373-387 (2016)
91. Kontopodis, E., et al. A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group. J. Chemother 25, 49-55 2013
92. Addeo, R., et al. Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clin. Breast Cancer 10, 301-306 (2010
93. Addeo, R., et al. Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. Cancer Chemother. Pharmacol. 70, 603-609 (2012
94. Pappas, P., Biziota, I., Marselos, M., & Briasoulis, E. Evaluation of antiproliferative and molecular effects of vinorelbine and its active metabolite 4 Odeacetyl-vinorelbine on human endothelial cells in an in vitro simulation model of metronomic chemotherapy. Eur. J. Cancer 6, 138-139 (2008
95. Mavroeidis, L., et al. Metronomic vinorelbine: anti-angiogenic activity in vitro in normoxic and severe hypoxic conditions, and severe hypoxia-induced resistance to its anti-proliferative effect with reversal by Akt inhibition. Int. J. Oncol. 47, 455-464 (2015
96. Vacca, A., et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. J. Clin. Oncol. 94, 4143-4155 (1999
97. Rock, B. M., Hengel, S. M., Rock, D. A., Wienkers, L. C., & Kunze, K. L. Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4. Mol. Pharmacol. 86, 665-674 (2014
98. Wang, J., Lou, P., Lesniewski, R., & Henkin, J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 14, 13-19 (2003
99. Gianni, L., et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol. 13, 180-190 (1995
100. Chatelut, E., Delord, J. P., & Canal, P. Toxicity patterns of cytotoxic drugs. Invest. New Drugs 21, 141-148 (2003
101. US National Library of Science ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02555007-term=02555007& rank=1 (2015
102. Bennouna, J., Saunders, M., & Douillard, J. Y. The role of UFT in metastatic colorectal cancer. Oncology 76, 301-310 (2009
103. Tanaka, F., Wada, H., & Fukushima, M. UFT and S-1 for treatment of primary lung cancer. Gen. Thorac. Cardiovasc. Surg. 58, 3-13 (2010
104. Kato, H., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N. Engl. J. Med. 350, 1713-1721 (2004
105. Bocci, G., & Francia, G. in Metronomic Chemotherapy. Pharmacology and Clinical Applications eds Bocci, G., & Francia, G.) 229-246 (Springer-Verlag, 2014
106. Paci, A., et al. Review of therapeutic drug monitoring of anticancer drugs part 1- cytotoxics. Eur. J. Cancer 50, 2010-2019 (2014
107. Pesenti, C., Gusella, M., SirS. M., & Miozzo, M. Germline oncopharmacogenetics, a promising field in cancer therapy. Cell. Oncol. (Dordr.) 38, 65-89 (2015
108. Hubbard, J. M., & Grothey, A. When less is more: maintenance therapy in colorectal cancer. Lancet 385, 1808-1810 (2015
109. Colleoni, F., et al. Low-dose oral cyclophosphamide-methotrexate maintenance (CMM) for receptor-negative early breast cancer (BC) [abstract]. J. Clin. Oncol. 33 (Suppl.), 1002 (2015
110. Malik, P. S., Raina, V., & Andre, N. Metronomics as maintenance treatment in oncology: time for chemo-switch. Front. Oncol. 4, 76 (2014
111. Dellapasqua, S., et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J. Clin. Oncol. 26, 4899-4905 (2008
112. Farkouh, A., et al. Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab. Anticancer Res. 34, 3669-3673 (2014
113. US National Library of Science ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02271464-term=NCT02271464& rank=1 (2015
114. Lutsiak, M. E., et al. Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105, 2862-2868 (2005
115. Wu, J., & Waxman, D. J. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8 T cell responses and immune memory. Oncoimmunology 4, e1005521 2015
116. Doloff, J. C., & Waxman, D. J. Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts. BMC Cancer 15, 375 (2015
117. Wu, J., & Waxman, D. J. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model. Cancer Lett. 353, 272-280 (2014
118. Doloff, J. C., Chen, C. S., & Waxman, D. J. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2. Mol. Cancer 13, 158 (2014
119. Doloff, J. C., & Waxman, D. J. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. Cancer Res. 72, 1103-1115 (2012
120. Jia, L., & Waxman, D. J. Thrombospondin 1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis. Cancer Lett. 330, 241-249 (2013
121. Shaked, Y., et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106, 3058-3061 (2005
122. Mancuso, P., et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108, 452-459 (2006
123. Calleri, A., et al. Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin. Cancer Res. 15, 7652-7657 (2009
124. Ge, Y., et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol. Immunother. 61, 353-362 (2012
125. Ghiringhelli, F., et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56, 641-648 (2007
126. Koumarianou, A., et al. The effect of metronomic versus standard chemotherapy on the regulatory to effector T cell equilibrium in cancer patients. Exp. Hematol. Oncol. 3, 3 (2014
127. Nars, M. S., & Kaneno, R. Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy. Int. J. Cancer 132, 2471-2478 (2013
128. Tagliamonte, M., et al. Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model. Cancer Immunol. Immunother. 64, 1305-1314 (2015
129. Chen, C. A., et al. Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol. Ther. 18, 1233-1243 (2010
130. Hermans, I. F., Chong, T. W., Palmowski, M. J., Harris, A. L., & Cerundolo, V. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res. 63, 8408-8413 (2003
131. Bouche, G., et al. Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan. ecancer 8, 463 (2014
132. Barbolosi, D., Ciccolini, J., Lacarelle, B., Barlesi, F., & Andre, N. Computational oncology- mathematical modelling of drug regimens for precision medicine. Nat. Rev. Clin. Oncol. 13, 242-254 (2015
133. Benzekry, S., et al. Metronomic reloaded: theoretical models bringing chemotherapy into the era of precision medicine. Semin. Cancer Biol. 35, 53-61 (2015
134. Faivre, C., Barbolosi, D., Pasquier, E., & Andre, N. A mathematical model for the administration of temozolomide: comparative analysis of conventional and metronomic chemotherapy regimens. Cancer Chemother. Pharmacol. 71, 1013-1019 (2013
135. Panetta, J. C., et al. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. Cancer Chemother. Pharmacol. 52, 435-441 (2003
136. Fioravanti, A., et al. Metronomic 5 fluorouracil, oxaliplatin and irinotecan in colorectal cancer. Eur. J. Pharmacol. 619, 8-14 (2009
137. Chow, A., et al. Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy. Invest. New Drugs 32, 47-59 (2014
138. Bocci, G., et al Cyclophosphamide-methotrexate-metronomic- chemotherapy for the palliative treatment of metaic breast cancer. A comparative pharmacoeconomic evaluation. Ann. Oncol. 16, 1243-1252 (2005
139. Andre, N., Banavali, S., Snihur, Y., & Pasquier, E. Has the time come for metronomics in low-income and middle-income countries- Lancet Oncol 14, e239-e248 (2013)
140. Craven, O., Hughes, C. A., Burton, A., Saunders, M. P., & Molassiotis, A. Is a nurse-led telephone intervention a viable alternative to nurse-led home care and standard care for patients receiving oral capecitabine- Results from a large prospective audit in patients with colorectal cancer. Eur. J. Cancer Care (Engl.) 22, 413-419 (2013)
141. Cowan, D. A. Drug testing. Essays Biochem. 44, 139-148 (2008
142. Adaway, J. E., & Keevil, B. G. Therapeutic drug monitoring and LC MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 883-884, 33-49 (2012
143. Millership, J. S. Microassay of drugs and modern measurement techniques. Paediatr. Anaesth. 21, 197-205 (2011
144. Anderson, L. W., Ludeman, S. M., Colvin, O. M., Grochow, L. B., & Strong, J. M. Quantitation of 4 hydroxycyclophosphamide/aldophosphamide in whole blood. J. Chromatogr. B Biomed. Appl. 667, 247-257 (1995
145. Gurney, H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J. Clin. Oncol. 14, 2590-2611 (1996
146. Gao, B., Klumpen, H. J., & Gurney, H. Dose calculation of anticancer drugs. Expert Opin. Drug Metab. Toxicol. 4, 1307-1319 (2008
147. Gurney, H. Developing a new framework for dose calculation. J. Clin. Oncol. 24, 1489-1490 (2006
148. Gurney, H. I don-t underdose my patients-do I- Lancet Oncol. 6, 637-638 (2005
149. Gurney, H. How to calculate the dose of chemotherapy. Br. J. Cancer 86, 1297-1302 (2002
150. Bergh, J., et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 356, 1384-1391 (2000
151. Zhang, A. Y., et al. Effect of toxicity-adjusted dose (TAD) of sunitinib on intra-patient variation of trough levels: a longitudinal study in metastatic renal cell cancer (mRCC) [abstract]. J. Clin. Oncol. 32 (Suppl.), 2597 (2014
152. Morabito, A., et al. A multicenter, randomised, phase II trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in advanced SCLC patients. The STAD 1 trial [abstract]. J. Clin. Oncol. 33 (Suppl.), 7505 (2015
153. Minasian, L., et al. Optimizing dosing of oncology drugs. Clin. Pharmacol. Ther. 96, 572-579 (2014